MA
MRNA icon

Montag & Associates’s Moderna MRNA Stock Holding History

Montag & Associates’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-986
Closed -$65.9K – 1022
2024
Q3 		$65.9K Sell
986
-300
-23% -$27.5K ﹤0.01% 555
2024
Q2 		$153K Sell
1,286
-100
-7% -$12.7K 0.01% 441
2024
Q1 		$148K Sell
1,386
-41
-3% -$4.13K 0.01% 447
2023
Q4 		$142K Sell
1,427
-865
-38% -$72.8K 0.01% 438
2023
Q3 		$237K Sell
2,292
-400
-15% -$44.6K 0.01% 364
2023
Q2 		$327K Sell
2,692
-2,747
-51% -$366K 0.02% 339
2023
Q1 		$835K Buy
5,439
+323
+6% +$53.3K 0.05% 230
2022
Q4 		$919K Buy
5,116
+3,315
+184% +$542K 0.06% 211
2022
Q3 		$213K Sell
1,801
-1,299
-42% -$197K 0.01% 345
2022
Q2 		$443K Sell
3,100
-6,856
-69% -$980K 0.03% 277
2022
Q1 		$1.72M Sell
9,956
-154
-2% -$25.9K 0.09% 182
2021
Q4 		$2.57M Sell
10,110
-4,489
-31% -$1.31M 0.13% 155
2021
Q3 		$5.62M Sell
14,599
-6,190
-30% -$2.28M 0.3% 92
2021
Q2 		$4.88M Buy
20,789
+763
+4% +$136K 0.26% 101
2021
Q1 		$2.62M Buy
20,026
+18,526
+1,235% +$2.68M 0.15% 145
2020
Q4 		$157K Buy
+1,500
New +$152K 0.01% 397

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Montag & Associates's MRNA Position: Q4 2024 in Review

Montag & Associates sold out of Moderna (MRNA) in Q4 2024, closing a stake of 986 shares — an estimated $65.9K sold.

Montag & Associates first reported a position in MRNA in Q4 2020 and held it in 16 quarters. The position peaked at $5.62M in Q3 2021. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Montag & Associates reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Montag & Associates sold 986 Moderna shares in Q4 2024, an estimated $65.9K.
  • Montag & Associates first reported a position in Moderna in Q4 2020 and held it in 16 quarters.
  • Montag & Associates's Moderna position peaked at $5.62M in Q3 2021.
  • 745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Montag & Associates's 13F filing for Q4 2024, filed 30 Jan 2025.